$3.84 Billion is the total value of Artal Group S.A.'s 108 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 81.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GS | Buy | GOLDMAN SACHS GROUP INCcall | $235,452,000 | +255.8% | 1,050,000 | +250.0% | 6.12% | +335.6% |
| GM | Buy | GENERAL MTRS COcall | $101,010,000 | +70.9% | 3,000,000 | +100.0% | 2.63% | +109.2% |
| MS | Buy | MORGAN STANLEYcall | $93,140,000 | +31.0% | 2,000,000 | +33.3% | 2.42% | +60.4% |
| WFC | Buy | WELLS FARGO CO NEWcall | $78,840,000 | +42.2% | 1,500,000 | +50.0% | 2.05% | +74.1% |
| RUBY | New | RUBIUS THERAPEUTICS, INC. | $69,811,000 | – | 2,908,791 | +100.0% | 1.82% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $48,360,000 | +6.8% | 4,000,000 | +37.9% | 1.26% | +30.6% |
| FATE | Buy | FATE THERAPEUTICS INC | $35,675,000 | +85.1% | 2,190,000 | +28.8% | 0.93% | +126.3% |
| ANAB | Buy | ANAPTYSBIO INC | $29,931,000 | +110.7% | 300,000 | +50.0% | 0.78% | +157.9% |
| BLUE | Buy | BLUEBIRD BIO INC | $25,550,000 | -4.2% | 175,000 | +2.9% | 0.66% | +17.3% |
| XNCR | Buy | XENCOR INC | $19,485,000 | +31.6% | 500,000 | +25.0% | 0.51% | +61.0% |
| TSRO | Buy | TESARO INCcall | $19,505,000 | +25.3% | 500,000 | +42.9% | 0.51% | +53.2% |
| XBI | New | SPDR SERIES TRUSTcall | $19,174,000 | – | 200,000 | +100.0% | 0.50% | – |
| MU | New | MICRON TECHNOLOGY INCcall | $18,092,000 | – | 400,000 | +100.0% | 0.47% | – |
| C | New | CITIGROUP INCcall | $17,935,000 | – | 250,000 | +100.0% | 0.47% | – |
| BABA | New | ALIBABA GROUP HLDG LTDcall | $16,476,000 | – | 100,000 | +100.0% | 0.43% | – |
| ARGX | Buy | ARGENX SEsponsored adr | $14,030,000 | +12.9% | 185,000 | +23.3% | 0.36% | +38.3% |
| WYNN | New | WYNN RESORTS LTDcall | $12,706,000 | – | 100,000 | +100.0% | 0.33% | – |
| AAL | New | AMERICAN AIRLS GROUP INCcall | $12,399,000 | – | 300,000 | +100.0% | 0.32% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INCcall | $12,090,000 | +54.8% | 1,000,000 | +100.0% | 0.32% | +89.8% |
| BABA | New | ALIBABA GROUP HLDG LTDsponsored ads | $10,709,000 | – | 65,000 | +100.0% | 0.28% | – |
| NIO | New | NIO INCspon ads | $10,470,000 | – | 1,500,000 | +100.0% | 0.27% | – |
| BOLD | Buy | AUDENTES THERAPEUTICS INC | $9,898,000 | +9.8% | 250,000 | +5.9% | 0.26% | +34.4% |
| SELB | Buy | SELECTA BIOSCIENCES INC | $8,732,000 | +31.8% | 561,540 | +12.3% | 0.23% | +61.0% |
| CMTA | Buy | CLEMENTIA PHARMACEUTICALS IN | $7,716,000 | +193.2% | 692,000 | +246.0% | 0.20% | +258.9% |
| REPL | New | REPLIMUNE GROUP INC | $7,245,000 | – | 450,000 | +100.0% | 0.19% | – |
| SPRO | Buy | SPERO THERAPEUTICS INC | $6,306,000 | +22.8% | 600,000 | +71.4% | 0.16% | +50.5% |
| YI | New | 111 INCads | $6,084,000 | – | 450,000 | +100.0% | 0.16% | – |
| ACIU | Buy | AC IMMUNE SA | $6,000,000 | +7.3% | 750,000 | +25.0% | 0.16% | +31.1% |
| TBIO | Buy | TRANSLATE BIO INC | $6,000,000 | -5.1% | 600,000 | +20.0% | 0.16% | +16.4% |
| LOGM | New | LOGMEIN INC | $5,792,000 | – | 65,000 | +100.0% | 0.15% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $5,730,000 | – | 200,000 | +100.0% | 0.15% | – |
| SGMO | Buy | SANGAMO THERAPEUTICS INC | $5,085,000 | +79.0% | 300,000 | +50.0% | 0.13% | +120.0% |
| CRSP | Buy | CRISPR THERAPEUTICS AGnamen akt | $4,435,000 | +51.0% | 100,000 | +100.0% | 0.12% | +85.5% |
| YMAB | New | Y MABS THERAPEUTICS INC | $3,984,000 | – | 150,000 | +100.0% | 0.10% | – |
| CMRX | Buy | CHIMERIX INC | $3,890,000 | +63.4% | 1,000,000 | +100.0% | 0.10% | +98.0% |
| ELAN | New | ELANCO ANIMAL HEALTH INC | $3,489,000 | – | 100,000 | +100.0% | 0.09% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $3,300,000 | +139.1% | 250,000 | +66.7% | 0.09% | +196.6% |
| FLEX | New | FLEX LTDord | $3,280,000 | – | 250,000 | +100.0% | 0.08% | – |
| CNAT | New | CONATUS PHARMACEUTICALS INC | $2,900,000 | – | 500,000 | +100.0% | 0.08% | – |
| GRTS | New | GRITSTONE ONCOLOGY INC | $2,848,000 | – | 200,000 | +100.0% | 0.07% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-07 |
| 13F-HR/A | 2024-05-17 |
| 4 | 2024-05-14 |
| 13F-HR | 2024-05-13 |
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.